ClinicalTrials.gg
CompletedNCT00834613Updated Aug 19, 2024Results posted

Metformin ER 750 mg Tablets, Fed

A Phase 1 interventional study of Glucophage® XR 750 mg Tablets and Metformin ER 750 mg Tablets in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to compare the rate and extent of absorption of metformin from a test formulation of Metformin ER 750 mg Tablets versus the reference Glucophage® XR 750 mg Tablets under fed conditions.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-smoking male or female with a minimum age of 18 years (i.e. non-smoker or non-tobacco user for at least 90 days prior to pre-study medical screening).
  • (BMI - weight/height²) greater than or equal to 19 kg/m² and less than or equal to 30 kg/m².
  • Availability of subject for the entire study period and willingness to adhere to protocol requirements, as evidenced by a signed Form.
  • Normal findings in the physical examination, 12-lead and vital signs (blood pressure between 100-140/60-90 mmHg, heart rate between 50-99 beats/min, temperature between 35.8ºC and 37.5ºC).
  • Negative for drugs of abuse, nicotine, alcohol, -surface antigen, and , and for female subjects, pregnancy (serum ß-CG).
  • No clinical laboratory values outside of the acceptable range as defined by BCR, unless the Principal Investigator decides they are not .
  • Female subjects who are surgically sterile for at least six months or for at least one year, or who will avoid pregnancy prior to the study, during the study and up until one month after the end of the study.

Exclusion criteria

Exclusion Criteria:

  • Known history of to metformin (e.g. Glucophage®) and/or related drugs such as glyburide (Diaβeta®, Euglucon®), tolbutamide (Orinase®, Apo-chlorpropamide), acetohexamide (Dimelor®), chlorpropamide (Diabinese®) and glipizide (Glucotrol®, Glibenese®).
  • Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurologic, hematological, liver, or kidney disease unless judged no by the Principal Investigator, or medical designate.
  • Known history or presence of food allergies, or any condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
  • Any clinically significant illness during the last four weeks prior to entry into this study.
  • Presence of any significant physical or organ abnormality.
  • Any subject with a history of drug abuse.
  • Any psychiatric or psychological disease (including depression) unless deemed not clinically significant by the Principal Investigator, or medical designate.
  • Use of any prescription medication within 14 days preceding entry into this study.
  • Use of over-the-counter (OTC) medication within seven days preceding entry into this study (except for spermicidal/barrier products).
  • Female subjects: use of oral contraceptives or contraceptive implants (Such as Norplant®) within 30 days prior to drug administration or a depot injection of progestogen drug (e.g. Depro-Provera®) within one year prior to drug administration.
  • Female subjects: presence of pregnancy or lactation.
  • Any subject who has had blood withdrawn within 56 days preceding this study, taken during the conduct of any clinical study at a facility other than BCR, or within the lockout period specified by a previous study conducted at BCR.
  • Participation in a clinical trial with an drug within 30 days preceding this study.
  • Any subject who has donated blood within 56 days preceding this study.
  • Any subject who has participated as a plasma donor in a plasmapheresis program within seven days preceding this study.
  • Significant or recent history of asthma (After 12 years of age).
  • Any subject with a recent (less than one year) history of alcohol abuse.
  • Intolerance to venipuncture.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    1

    Drug: Metformin ER 750 mg Tablets

  • Active comparator
    2

    Drug: Glucophage® XR 750 mg Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum Observed Concentration of Drug Substance in Plasma)

    Bioequivalence based on Cmax.

    Time frame: Blood samples collected over a 36 hour period.

  2. AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

    Bioequivalence based on AUC0-t.

    Time frame: Blood samples collected over a 36 hour period.

  3. AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

    Bioequivalence based on AUC0-inf.

    Time frame: Blood samples collected over a 36 hour period.

07

Results

Posted Aug 18, 2009

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneTest (Metformin) FirstReference (Glucophage®) First
Started1616
Completed1516
Not completed10
Withdrew: Protocol violation10
Washout of 7 Days
Participant flow — Washout of 7 Days
MilestoneTest (Metformin) FirstReference (Glucophage®) First
Started1516
Completed1516
Not completed00
Second Intervention
Participant flow — Second Intervention
MilestoneTest (Metformin) FirstReference (Glucophage®) First
Started1516
Completed1516
Not completed00

Outcome measures

PrimaryCmax (Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Cmax.

Time frame:
Blood samples collected over a 36 hour period.
Reported as:
Mean · ng/mL
Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
ng/mLTest (Metformin)Reference (Glucophage®)
Cmax (Maximum Observed Concentration of Drug Substance in Plasma)853.63 ± 112.2824.89 ± 112.58
Statistical analysis
  • Test (Metformin) vs Reference (Glucophage®) · Ratio of the t/r geometric mean x 100: 103.45 · 90% CI 99.87 to 107.15Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.
PrimaryAUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on AUC0-t.

Time frame:
Blood samples collected over a 36 hour period.
Reported as:
Mean · ng*h/mL
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
ng*h/mLTest (Metformin)Reference (Glucophage®)
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)8965.41 ± 1417.839193.38 ± 1611.87
Statistical analysis
  • Test (Metformin) vs Reference (Glucophage®) · Ratio of the t/r geometric mean x 100: 97.63 · 90% CI 95.21 to 100.11Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.
PrimaryAUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on AUC0-inf.

Time frame:
Blood samples collected over a 36 hour period.
Reported as:
Mean · ng*h/mL
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
ng*h/mLTest (Metformin)Reference (Glucophage®)
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)9162.85 ± 1415.99397.52 ± 1620.32
Statistical analysis
  • Test (Metformin) vs Reference (Glucophage®) · Ratio of the t/r geometric mean x 100: 97.63 · 90% CI 95.22 to 100.1Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Test (Metformin) FirstReference (Glucophage®) FirstTotal
<=18 years000
Between 18 and 65 years161632
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Test (Metformin) FirstReference (Glucophage®) FirstTotal
Female10515
Male61117
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Test (Metformin) FirstReference (Glucophage®) FirstTotal
Asian033
Black033
White161026
Region of Enrollment
Region of Enrollment(participants)Test (Metformin) FirstReference (Glucophage®) FirstTotal
Canada161632
08

Study locations

1 site
  • Biovail Contract Research
    Toronto, Ontario M1L4S4, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003, a primary completion of Aug 2003 and a completion of Aug 2003. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 6 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2009
First posted
Feb 3, 2009
Start
Aug 2003
Primary completionActual
Aug 2003
CompletionActual
Aug 2003
Results first posted
Aug 18, 2009
Last update
Aug 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00834613
First posted
Feb 3, 2009
Start date
Aug 2003
Primary completion
Aug 2003
Completion
Aug 2003
Results posted
Aug 18, 2009
Last update
Aug 19, 2024

Study contacts

Paul Y. Tam, M.D.
principal investigator · Biovail Contract Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion